Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Belite Bio Inc

BLTE ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$162.80

▼ -2.09%

Market Cap $6.56B · Vol 81.04K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.56B

Mid Cap

Div Yield

N/A

EPS Growth

-44.02%

YoY

RSI (14)

53.71

Momentum

Beta

-1.26

vs Market

52W High

$200.00

18.60% below

52W Low

$60.00

171.33% above

Volume

81.04K

Avg 50.96K

P/B

8.17

Price-to-book

ROE

-16.94%

Return on equity

Free Float

55.29%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Belite Bio Inc (BLTE) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BLTE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.15%

+10.99%

+8.57%

-7.11%

YTD

+1.78%

+136.01%

+634.33%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-77,611,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-16.94%
ROA · ROIC	-16.64% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	8.17
P/FCF	N/A
EPS Growth	-44.02%
Outstanding Shares	40.27M

Technical Indicators

50-Day SMA	$152.40
200-Day SMA	$153.86
RSI (14)	53.71
Beta	-1.26
52-Week High	$200.00
52-Week Low	$60.00

Volume Today	81.04K
Avg Daily Volume (30D)	50.96K
Relative Volume	1.59x
Volatility (10D)	53.30
Volatility (30D)	45.56
Free Float	55.29%

Analyst Consensus

BUY

Current Price $162.80

Mean Target $214.00

52W Low$60.00 52W High$200.00

Current

Target

$60.00 $200.00

Current Analyst target

+31.45% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG016LJYTW4

ISINUS07782B1044

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.